Cargando…
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk
AIM: To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 diabetes mellitus. METHODS: 213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518654/ https://www.ncbi.nlm.nih.gov/pubmed/26223257 http://dx.doi.org/10.1186/s12933-015-0254-8 |
_version_ | 1782383391946047488 |
---|---|
author | Derosa, Giuseppe Mugellini, Amedeo Pesce, Rosa M D’Angelo, Angela Maffioli, Pamela |
author_facet | Derosa, Giuseppe Mugellini, Amedeo Pesce, Rosa M D’Angelo, Angela Maffioli, Pamela |
author_sort | Derosa, Giuseppe |
collection | PubMed |
description | AIM: To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 diabetes mellitus. METHODS: 213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B). We assessed at baseline, at the end of Phase A, and at the end of Phase B the levels of some new emerging biomarkers of cardiovascular risk including: high sensitivity C-reactive protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), myeloperoxidase (MPO), soluble CD40 ligand (sCDL40). RESULTS: Compared to baseline, at the end of Phase A, patients treated with amlodipine 5 mg + ASA 100 mg showed a statistically significant reduction of Hs-CRP (−15.0%), TNF-α (−21.7%), MPO (−9.7%), and sCDL40 (−15.7%), and a statistically significant increase of ADN (+15.0%). These values were significantly better than the ones obtained with amlodipine alone. Similarly, at the end of Phase B, amlodipine 10 mg + ASA significantly lowered Hs-CRP (−18.8%), TNF-α (−15.0%), MPO (−9.2%), and sCDL40 (−20.0%) and increased ADN (+11.8%), with a better effect compared to amlodipine alone. CONCLUSION: All biomarkers considered were significantly improved by ASA addition. These data suggest that the use of ASA in primary prevention could be useful in patients with type 2 diabetes mellitus and hypertension. Trial registration: ClinicalTrials.gov: NCT02064218 |
format | Online Article Text |
id | pubmed-4518654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45186542015-07-30 A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk Derosa, Giuseppe Mugellini, Amedeo Pesce, Rosa M D’Angelo, Angela Maffioli, Pamela Cardiovasc Diabetol Original Investigation AIM: To evaluate the relevance of adding acetylsalicylic acid (ASA) in primary prevention in subjects with type 2 diabetes mellitus. METHODS: 213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B). We assessed at baseline, at the end of Phase A, and at the end of Phase B the levels of some new emerging biomarkers of cardiovascular risk including: high sensitivity C-reactive protein (Hs-CRP), adiponectin (ADN), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), myeloperoxidase (MPO), soluble CD40 ligand (sCDL40). RESULTS: Compared to baseline, at the end of Phase A, patients treated with amlodipine 5 mg + ASA 100 mg showed a statistically significant reduction of Hs-CRP (−15.0%), TNF-α (−21.7%), MPO (−9.7%), and sCDL40 (−15.7%), and a statistically significant increase of ADN (+15.0%). These values were significantly better than the ones obtained with amlodipine alone. Similarly, at the end of Phase B, amlodipine 10 mg + ASA significantly lowered Hs-CRP (−18.8%), TNF-α (−15.0%), MPO (−9.2%), and sCDL40 (−20.0%) and increased ADN (+11.8%), with a better effect compared to amlodipine alone. CONCLUSION: All biomarkers considered were significantly improved by ASA addition. These data suggest that the use of ASA in primary prevention could be useful in patients with type 2 diabetes mellitus and hypertension. Trial registration: ClinicalTrials.gov: NCT02064218 BioMed Central 2015-07-30 /pmc/articles/PMC4518654/ /pubmed/26223257 http://dx.doi.org/10.1186/s12933-015-0254-8 Text en © Derosa et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Derosa, Giuseppe Mugellini, Amedeo Pesce, Rosa M D’Angelo, Angela Maffioli, Pamela A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title_full | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title_fullStr | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title_full_unstemmed | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title_short | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
title_sort | study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518654/ https://www.ncbi.nlm.nih.gov/pubmed/26223257 http://dx.doi.org/10.1186/s12933-015-0254-8 |
work_keys_str_mv | AT derosagiuseppe astudyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT mugelliniamedeo astudyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT pescerosam astudyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT dangeloangela astudyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT maffiolipamela astudyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT derosagiuseppe studyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT mugelliniamedeo studyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT pescerosam studyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT dangeloangela studyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk AT maffiolipamela studyabouttherelevanceofaddingacetylsalicylicacidinprimarypreventioninsubjectswithtype2diabetesmellituseffectsonsomenewemergingbiomarkersofcardiovascularrisk |